GFAP and Alzheimer disease: This study evaluated the potential of plasma biomarkers of AD (p-tau217, GFAP, NfL and Aβ42/40) in a population-based African cohort of older adults (≥ 50 years), by investigating the association of the biomarkers with cognitive status.